Mitchell Sinkler & Starr PA Purchases 160 Shares of Novartis AG $NVS

Mitchell Sinkler & Starr PA grew its position in Novartis AG (NYSE:NVS) by 5.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,343 shares of the company’s stock after acquiring an additional 160 shares during the quarter. Mitchell Sinkler & Starr PA’s holdings in Novartis were worth $405,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in NVS. Brighton Jones LLC increased its stake in Novartis by 76.5% in the 4th quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock worth $599,000 after acquiring an additional 2,666 shares during the last quarter. Rhumbline Advisers increased its stake in Novartis by 11.1% in the 1st quarter. Rhumbline Advisers now owns 38,600 shares of the company’s stock worth $4,303,000 after acquiring an additional 3,846 shares during the last quarter. Wealthcare Advisory Partners LLC increased its stake in Novartis by 9.0% in the 1st quarter. Wealthcare Advisory Partners LLC now owns 3,041 shares of the company’s stock worth $339,000 after acquiring an additional 252 shares during the last quarter. GAMMA Investing LLC increased its stake in Novartis by 29.9% in the 1st quarter. GAMMA Investing LLC now owns 6,524 shares of the company’s stock worth $727,000 after acquiring an additional 1,500 shares during the last quarter. Finally, Simon Quick Advisors LLC boosted its holdings in shares of Novartis by 34.6% in the 1st quarter. Simon Quick Advisors LLC now owns 5,732 shares of the company’s stock worth $639,000 after purchasing an additional 1,475 shares during the period. Institutional investors own 13.12% of the company’s stock.

Novartis Price Performance

NVS opened at $130.05 on Friday. The business has a fifty day moving average of $125.14 and a 200 day moving average of $117.91. Novartis AG has a 52-week low of $96.06 and a 52-week high of $133.55. The company has a quick ratio of 0.62, a current ratio of 0.82 and a debt-to-equity ratio of 0.53. The stock has a market cap of $274.72 billion, a P/E ratio of 18.93, a PEG ratio of 1.80 and a beta of 0.64.

Novartis (NYSE:NVS) last issued its earnings results on Thursday, July 17th. The company reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.38 by $0.04. The business had revenue of $14.05 billion during the quarter, compared to analyst estimates of $13.94 billion. Novartis had a return on equity of 41.08% and a net margin of 25.64%.Novartis’s revenue was up 12.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.97 EPS. As a group, sell-side analysts anticipate that Novartis AG will post 8.45 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on NVS shares. The Goldman Sachs Group reiterated a “sell” rating and issued a $118.00 target price (down previously from $119.00) on shares of Novartis in a report on Friday, September 12th. Weiss Ratings reiterated a “buy (b)” rating on shares of Novartis in a report on Wednesday. Morgan Stanley upgraded Novartis from an “underweight” rating to an “equal weight” rating and set a $123.00 target price for the company in a report on Friday, August 8th. Wall Street Zen upgraded Novartis from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Novartis in a report on Thursday, August 21st. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $120.33.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.